Deschloroketamine: Difference between revisions
>Unity Placed SummarySheet above SubstanceBox. |
>Unity Intro modifications to conform to style guidelines. |
||
Line 2: | Line 2: | ||
{{SubstanceBox/Deschloroketamine}} | {{SubstanceBox/Deschloroketamine}} | ||
'''Deschloroketamine''' (also known as ''' | '''Deschloroketamine''' (also known as '''2'-Oxo-PCM''', '''O-PCM''', '''DXE''', and '''DCK''') is a novel synthetic [[psychoactive class::dissociative]] substance of the [[chemical class::arylcyclohexylamine]] chemical class which produces [[dissociative]], [[pain relief|anesthetic]] and [[hallucinogenic]] effects when [[Routes of administration|administered]].<ref name="name">Synthesis and in vitro evaluation of (18)F-labelled S-fluoroalkyl diarylguanidines: Novel high-affinity NMDA receptor antagonists for imaging with PET (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/20138515</ref><ref name="patent">Patent US 3254124 - Aminoketones and methods for their production | http://www.google.com/patents/US3254124</ref> | ||
Early discussion over DCK has revolved around speculation over claims of antibacterial or immunosuppressant properties. If this speculation is valid, it | Early discussion over DCK has revolved around speculation over claims of antibacterial or immunosuppressant properties. If this speculation is valid, it is possible that its prolonged use could potentially pose a serious threat to one's health and immune system, which is why misuse of this substance is highly discouraged and caution to avoid treating it like its parent compound, [[ketamine]], is advised.<ref name="DCKAntibacterial">Preiss, D., & Tartar, A. (1998). U.S. Patent No. US5811464. Washington, DC: U.S. Patent and Trademark Office. | https://www.google.com/patents/US5811464</ref> | ||
DCK has recently become easily accessible through online [[research chemical]] vendors<ref name="name" /> where it is being sold as a [[designer drug]].<ref>Characterization of the [[designer drug]] deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/26661982</ref><ref>Alert: descloroketamina sold as ketamine in Barcelona | http://energycontrol.org/analisis-de-sustancias/resultados/alertas/560-alerta-descloroketamina-vendida-como-ketamina-en-barcelona.html</ref><ref>The unknown effects of drought ketamine | http://www.vice.com/es/read/los-efectos-desconocidos-de-la-sequia-de-ketamina-719</ref> | DCK has recently become easily accessible through online [[research chemical]] vendors<ref name="name" /> where it is being sold as a [[designer drug]].<ref>Characterization of the [[designer drug]] deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/26661982</ref><ref>Alert: descloroketamina sold as ketamine in Barcelona | http://energycontrol.org/analisis-de-sustancias/resultados/alertas/560-alerta-descloroketamina-vendida-como-ketamina-en-barcelona.html</ref><ref>The unknown effects of drought ketamine | http://www.vice.com/es/read/los-efectos-desconocidos-de-la-sequia-de-ketamina-719</ref> | ||
Very little data exists about the pharmacological properties, metabolism, and toxicity of DCK, and it has a very brief history of human usage. It is strongly recommended that one use [[responsible drug use|harm reduction practices]] | Very little data exists about the pharmacological properties, metabolism, and toxicity of DCK, and it has a very brief history of human usage. It is strongly recommended that one use [[responsible drug use|harm reduction practices]] if choosing to use this substance. | ||
==Chemistry== | ==Chemistry== |